default author photo

Wouter H. van Geffen

affiliation not provided to SSRN

SCHOLARLY PAPERS

2

DOWNLOADS

69

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Volume and location of lung cancer from screen-detected nodules to two-years follow-up: Post hoc analysis from the UK Lung Cancer Screening (UKLS) Trial

Number of pages: 32 Posted: 16 Dec 2025
University of Groningen, affiliation not provided to SSRN, University of Liverpool, University of Liverpool, Queen Mary University of London, University of Groningen, affiliation not provided to SSRN, affiliation not provided to SSRN, Imperial College London - National Heart and Lung Institute, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 39 (1,196,171)

Abstract:

Loading...

Lung cancer, screening, location, volume, UKLS

2.

Model-Informed Approaches to Develop Cost-Saving Dosing Strategies for Pembrolizumab

Number of pages: 20 Posted: 17 Apr 2026
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Erasmus University Rotterdam (EUR) - Department of Pulmonary Medicine, affiliation not provided to SSRN, Netherlands Cancer Institute Antoni van Leeuwenhoek, affiliation not provided to SSRN, Leiden University Medical Centre, Leiden University - Leiden University Medical Center (LUMC), Amsterdam Academic Medical Center, University of Groningen - Department of Pulmonary Diseases, Maastricht University, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Groningen - University Medical Center Groningen, affiliation not provided to SSRN, Leiden University - Department of Clinical Pharmacy and Toxicology, Leiden University - Department of Clinical Pharmacy and Toxicology and Radboud University Nijmegen - Department of Pharmacy and Radboud Center for Infectious Diseases
Downloads 30 (1,359,097)

Abstract:

Loading...

pembrolizumab, pharmacokinetics, modeling and simulation, cost-effectiveness